Growth hormone responses to growth hormone-releasing hormone in hand-schiiller-christian disease

Marie C. Gelalo, Donald (Lynn) Loriaux, George R. Merriam

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Bolus doses of GH-releasing hormone (GHRH), I pg/kg i.v., were given to two groups of adult patients with growth hormone deficiency (GHD): 9 with Hand-Schiiller-Christian disease (HSCD, presumed hypothalamic GHD) and 9 with idiopathic GHD (IGHD, etiology unknown). Six patients in each group were then given further GHRH doses daily for 5 days, and the GH responses to GHRH were measured over 3 h on day 1 and day 5. Plasma levels of insulin-like growth factor-I (IGF-I) were measured twice daily on days I and 5 during GHRH treatment. All patients with HSCI) had measurable GH responses to the first dose of GHRH. with a mean peak response of 6.4 ± 2.1 ng/ml (X ± SE). Only 5 of 9 patients with IGHD had GH responses above the detection limits of the assay; their mean peak response, 1.3 + 0.2 ng/ml, was significantly lower than the GH responses of the HSCD patients (p <0.05). Responses in both groups of patients were lower than those previously observed in normal adult men (35 ± 8 ng/ml; p l<0.01). Five days of daily stimulation with GHRH significantly (p <0.01) increased the GH response in both groups of patients. The rise was greater in patients with HSCD than with IGHD (HSCD, 5.1 ± 2.5 ng/ml on day I, vs. 12.0 ± 6.8 ng/ml on day 5; IGHD, 1.4 ± 0.3 ng/ml vs. 2.9 ± 0.6 ng/ml). Plasma IGF-I levels rose significantly over the 5 days in both groups; this rise was also greater in the HSCD patients (HSCD, 0.37 ± 0.06 vs. 0.64 ± 0.1 U/ml; IGHD, 0.38 ± 0.12 vs. 0.45 ± 0.12 U/ml, p <0.05). Responses in this group of HSCD patients confirm the expectation that patients with ‘pure’ hypothalamic GHD should have GH responses to GHRH, and that diminished initial responses reflect somatotroph atrophy which can be reversed with repeated GHRH stimulation.

Original languageEnglish (US)
Pages (from-to)259-264
Number of pages6
JournalNeuroendocrinology
Volume50
Issue number3
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Growth Hormone-Releasing Hormone
Growth Hormone
Hand
Hormones
Hypothalamic Hormones
Insulin-Like Growth Factor I
Somatotrophs
Atrophy
Limit of Detection

Keywords

  • Growth hormone
  • Growth hormone-releasing hormone
  • Hand-Schüller-Christian disease

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Cellular and Molecular Neuroscience
  • Endocrine and Autonomic Systems
  • Neuroscience(all)

Cite this

Growth hormone responses to growth hormone-releasing hormone in hand-schiiller-christian disease. / Gelalo, Marie C.; Loriaux, Donald (Lynn); Merriam, George R.

In: Neuroendocrinology, Vol. 50, No. 3, 1989, p. 259-264.

Research output: Contribution to journalArticle

@article{446a58c25e1c427184a36cea1cecdc54,
title = "Growth hormone responses to growth hormone-releasing hormone in hand-schiiller-christian disease",
abstract = "Bolus doses of GH-releasing hormone (GHRH), I pg/kg i.v., were given to two groups of adult patients with growth hormone deficiency (GHD): 9 with Hand-Schiiller-Christian disease (HSCD, presumed hypothalamic GHD) and 9 with idiopathic GHD (IGHD, etiology unknown). Six patients in each group were then given further GHRH doses daily for 5 days, and the GH responses to GHRH were measured over 3 h on day 1 and day 5. Plasma levels of insulin-like growth factor-I (IGF-I) were measured twice daily on days I and 5 during GHRH treatment. All patients with HSCI) had measurable GH responses to the first dose of GHRH. with a mean peak response of 6.4 ± 2.1 ng/ml (X ± SE). Only 5 of 9 patients with IGHD had GH responses above the detection limits of the assay; their mean peak response, 1.3 + 0.2 ng/ml, was significantly lower than the GH responses of the HSCD patients (p <0.05). Responses in both groups of patients were lower than those previously observed in normal adult men (35 ± 8 ng/ml; p l<0.01). Five days of daily stimulation with GHRH significantly (p <0.01) increased the GH response in both groups of patients. The rise was greater in patients with HSCD than with IGHD (HSCD, 5.1 ± 2.5 ng/ml on day I, vs. 12.0 ± 6.8 ng/ml on day 5; IGHD, 1.4 ± 0.3 ng/ml vs. 2.9 ± 0.6 ng/ml). Plasma IGF-I levels rose significantly over the 5 days in both groups; this rise was also greater in the HSCD patients (HSCD, 0.37 ± 0.06 vs. 0.64 ± 0.1 U/ml; IGHD, 0.38 ± 0.12 vs. 0.45 ± 0.12 U/ml, p <0.05). Responses in this group of HSCD patients confirm the expectation that patients with ‘pure’ hypothalamic GHD should have GH responses to GHRH, and that diminished initial responses reflect somatotroph atrophy which can be reversed with repeated GHRH stimulation.",
keywords = "Growth hormone, Growth hormone-releasing hormone, Hand-Sch{\"u}ller-Christian disease",
author = "Gelalo, {Marie C.} and Loriaux, {Donald (Lynn)} and Merriam, {George R.}",
year = "1989",
doi = "10.1159/000125231",
language = "English (US)",
volume = "50",
pages = "259--264",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Growth hormone responses to growth hormone-releasing hormone in hand-schiiller-christian disease

AU - Gelalo, Marie C.

AU - Loriaux, Donald (Lynn)

AU - Merriam, George R.

PY - 1989

Y1 - 1989

N2 - Bolus doses of GH-releasing hormone (GHRH), I pg/kg i.v., were given to two groups of adult patients with growth hormone deficiency (GHD): 9 with Hand-Schiiller-Christian disease (HSCD, presumed hypothalamic GHD) and 9 with idiopathic GHD (IGHD, etiology unknown). Six patients in each group were then given further GHRH doses daily for 5 days, and the GH responses to GHRH were measured over 3 h on day 1 and day 5. Plasma levels of insulin-like growth factor-I (IGF-I) were measured twice daily on days I and 5 during GHRH treatment. All patients with HSCI) had measurable GH responses to the first dose of GHRH. with a mean peak response of 6.4 ± 2.1 ng/ml (X ± SE). Only 5 of 9 patients with IGHD had GH responses above the detection limits of the assay; their mean peak response, 1.3 + 0.2 ng/ml, was significantly lower than the GH responses of the HSCD patients (p <0.05). Responses in both groups of patients were lower than those previously observed in normal adult men (35 ± 8 ng/ml; p l<0.01). Five days of daily stimulation with GHRH significantly (p <0.01) increased the GH response in both groups of patients. The rise was greater in patients with HSCD than with IGHD (HSCD, 5.1 ± 2.5 ng/ml on day I, vs. 12.0 ± 6.8 ng/ml on day 5; IGHD, 1.4 ± 0.3 ng/ml vs. 2.9 ± 0.6 ng/ml). Plasma IGF-I levels rose significantly over the 5 days in both groups; this rise was also greater in the HSCD patients (HSCD, 0.37 ± 0.06 vs. 0.64 ± 0.1 U/ml; IGHD, 0.38 ± 0.12 vs. 0.45 ± 0.12 U/ml, p <0.05). Responses in this group of HSCD patients confirm the expectation that patients with ‘pure’ hypothalamic GHD should have GH responses to GHRH, and that diminished initial responses reflect somatotroph atrophy which can be reversed with repeated GHRH stimulation.

AB - Bolus doses of GH-releasing hormone (GHRH), I pg/kg i.v., were given to two groups of adult patients with growth hormone deficiency (GHD): 9 with Hand-Schiiller-Christian disease (HSCD, presumed hypothalamic GHD) and 9 with idiopathic GHD (IGHD, etiology unknown). Six patients in each group were then given further GHRH doses daily for 5 days, and the GH responses to GHRH were measured over 3 h on day 1 and day 5. Plasma levels of insulin-like growth factor-I (IGF-I) were measured twice daily on days I and 5 during GHRH treatment. All patients with HSCI) had measurable GH responses to the first dose of GHRH. with a mean peak response of 6.4 ± 2.1 ng/ml (X ± SE). Only 5 of 9 patients with IGHD had GH responses above the detection limits of the assay; their mean peak response, 1.3 + 0.2 ng/ml, was significantly lower than the GH responses of the HSCD patients (p <0.05). Responses in both groups of patients were lower than those previously observed in normal adult men (35 ± 8 ng/ml; p l<0.01). Five days of daily stimulation with GHRH significantly (p <0.01) increased the GH response in both groups of patients. The rise was greater in patients with HSCD than with IGHD (HSCD, 5.1 ± 2.5 ng/ml on day I, vs. 12.0 ± 6.8 ng/ml on day 5; IGHD, 1.4 ± 0.3 ng/ml vs. 2.9 ± 0.6 ng/ml). Plasma IGF-I levels rose significantly over the 5 days in both groups; this rise was also greater in the HSCD patients (HSCD, 0.37 ± 0.06 vs. 0.64 ± 0.1 U/ml; IGHD, 0.38 ± 0.12 vs. 0.45 ± 0.12 U/ml, p <0.05). Responses in this group of HSCD patients confirm the expectation that patients with ‘pure’ hypothalamic GHD should have GH responses to GHRH, and that diminished initial responses reflect somatotroph atrophy which can be reversed with repeated GHRH stimulation.

KW - Growth hormone

KW - Growth hormone-releasing hormone

KW - Hand-Schüller-Christian disease

UR - http://www.scopus.com/inward/record.url?scp=0024469270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024469270&partnerID=8YFLogxK

U2 - 10.1159/000125231

DO - 10.1159/000125231

M3 - Article

C2 - 2507952

AN - SCOPUS:0024469270

VL - 50

SP - 259

EP - 264

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 3

ER -